FDA Acts to Prevent Contamination Problems With Triad Antiseptic Products

Seizure of drug products is an effective remedy when there is evidence of continued poor compliance with cGMP requirements. Following a drug product seizure, companies often agree to a wide range of changes and improvements to their drug manufacturing practices at their facilities.

U.S. Marshals, at the request of the U.S. Food and Drug Administration, yesterday seized more than $6 million in products distributed by Triad Group Inc., at the company's facility in Hartland, Wis.

Triad Group and H & P Industries are owned and managed by the same parties. A variety of drug products were seized, including povidone-iodine and benzalkonium chloride antiseptic products, cough and cold products, nasal sprays, suppositories, medicated wipes, antifungal creams, hemorrhoidal wipes, in-process drug products, and raw materials.

"We took this action to stop Triad from continuing to distribute products, which may pose a risk to public health," said Dara Corrigan, FDA associate commissioner for regulatory affairs.